Fig 1: Celastrol inhibited tumor growth in CDX and PDX mouse models. (A) Images of tumors from mice engrafted with PANC-1 cells after the intraperitoneal administration of celastrol (5 mg/kg). (B-D) Tumor weight, body weight and tumor volume after the administration of celastrol (5 mg/kg). (E) IHC analysis of the sorcin, FBXL12 and ALDH1A1 protein levels in a xenograft tumor model after the administration of celastrol. (F) Images of tumors from PDX model mice after the intraperitoneal administration of celastrol (5 mg/kg). (G-I) Tumor weight, body weight and tumor volume after the administration of celastrol to the PDX model (5 mg/kg). (J) IHC analysis of the sorcin, FBXL12 and ALDH1A1 protein levels in the PDX tumor model after the administration of celastrol
Fig 2: Sorcin mediated the nuclear translocation of PAX5 to regulate FBXL12 transcription. (A) GO analysis of proteins whose expression significantly changed after sorcin was knocked down by shRNA according to the proteomics results. (B) GO proteomics analysis of proteins whose expression significantly changed after sorcin overexpression. (C) Schematic illustration of the cloned fragments in the human FBXL12 promoter. (D) Luciferase activity of the FBXL12 promoter fragments in PANC-1 and Capan-2 cells. (E) Base frequency rule and possible transcription factor-binding site analysis. (F) Ch-IP analysis of the five predicted PAX5 binding sites in the FBXL12 promoter sequence. IgG was used as a negative control. (G) Luciferase activity of the P6 promoter after mutation of site 2 or site 4 in PANC-1 and Capan-2 cells. (H) Western blotting analysis of PAX5, FBXL12 and ALDH1A1 expression in PANC-1, Capan-2 and AsPC-1 cells after PAX5 knockdown or overexpression. (I) Analysis of the interaction between PAX5 and sorcin after transfection with the pCMV-Flag-sorcin vector by coimmunoprecipitation with an anti-Flag antibody followed by Western blotting analysis. (J) Analysis of the interaction between PAX5 and sorcin after transfection with the pCMV-Flag-PAX5 vector by coimmunoprecipitation with an anti-Flag antibody followed by Western blotting analysis. (K) Immunofluorescence analysis of PAX5 nuclear translocation in sorcin-knockdown xenograft tumor tissues. (L) Statistical analysis of the immunofluorescence intensity of PAX5 nuclear translocation in sorcin-knockdown xenograft tumor tissues. (M) Western blotting analysis of PAX5 expression in the nucleus and cytoplasm of PANC-1, AsPC-1 and Capan-2 cells after sorcin knockdown and overexpression. (N) Immunofluorescence analysis of PAX5 levels in the nucleus and cytoplasm in PANC-1 cells after sorcin knockdown and overexpression
Fig 3: Celastrol induced ferroptosis by promoting the nuclear translocation of PAX5. (A)Coimmunoprecipitation analysis of the interaction between PAX5 and sorcin after treatment with celastrol for 48 h. (B) Western blotting analysis of PAX5 levels in the nucleus and cytoplasm of PANC-1, Capan-2 and AsPC-1 cells after treatment with the indicated concentrations of celastrol for 48 h. (C) Immunofluorescence analysis of PAX5 levels in the nucleus and cytoplasm after treatment with celastrol for 48 h. (D) Quantitative analysis of FBXL12 gene expression after treatment with the indicated concentrations of celastrol for 24 h. (E) Western blotting analysis of FBXL12 and ALDH1A1 expression in PANC-1, Capan-2, AsPC-1 and PaTu8988T cells after treatment with celastrol at the indicated concentrations for 48 h. (F) Coimmunoprecipitation analysis of ALDH1A1 ubiquitylation after treatment with the indicated concentrations of celastrol for 48 h. (G) Representative images and statistical analysis of lipid ROS levels in PANC-1 cells after treatment with the indicated concentrations of celastrol for 48 h. (H) Representative images and statistical analysis of lipid ROS levels in Capan-2 cells after treatment with the indicated concentrations of celastrol for 48 h. (I) Analysis of malondialdehyde levels after treatment with the indicated concentrations of celastrol for 48 h. (J) Representative images and statistical analysis of lipid ROS levels in PANC-1 cells treated with celastrol combined with RSL3 (1 µM) or erastin (2 µM). (K) Representative images and statistical analysis of lipid ROS levels in Capan-2 cells treated with celastrol combined with RSL3 (1 µM) or erastin (1 µM). (L) Analysis of the viability of the indicated PANC-1 cells treated with celastrol combined with RSL3 or erastin. (M) Analysis of the viability of the indicated Capan-2 cells treated with celastrol combined with RSL3 or erastin. (N) Comparison of the cell viability and lipid ROS levels of the indicated cells. (O) Analysis of the viability of the indicated cells treated with celastrol combined with liproxstatin-1 or ferrostatin-1.
Fig 4: FBXL12 inhibited pancreatic cancer progression by inhibiting ALDH1A1 levels. (A) Representative images of PANC-1 and Capan-2 cell migration after FBXL12 was knocked down by siRNA or overexpressed. (B) Statistical analysis of cell migration after FBXL12 was knocked down by siRNA or overexpressed. (C) Representative images of tumorsphere formation by PANC-1 and Capan-2 cells after FBXL12 was knocked down by siRNA or overexpressed. (D) Statistical analysis of tumorsphere formation after FBXL12 was knocked down by siRNA or overexpressed. (E-F) Western blotting analysis and statistical analysis of FBXL12 and ALDH1A1 expression in PANC-1, Capan-2 and AsPC-1 cells after FBXL12 was knocked down by siRNA or overexpressed. (G) Representative images of lipid ROS levels in sorcin-knockdown cells after transfection with FBXL12 siRNAs. (H) Statistical analysis of lipid ROS levels in sorcin-knockdown cells after transfection with FBXL12 siRNAs. (I) Western blotting analysis of ALDH1A1 expression in sorcin-knockdown cells after transfection with FBXL12 siRNAs
Fig 5: FBXL12 mediated ALDH1A1 ubiquitination. (A) Western blotting analysis of ALDH1A1 protein levels in PANC-1, Capan-2 and AsPC-1 cells after treatment with MG132 at 10 µM for the indicated times. (B) Western blotting analysis of ALDH1A1 protein levels in PANC-1, Capan-2 and AsPC-1 cells after treatment with the protein synthesis inhibitor cycloheximide at 10 µM for the indicated times. (C) Statistical analysis of ALDH1A1 protein levels in PANC-1, Capan-2 and AsPC-1 cells after treatment with MG132 at 10 µM for the indicated times. (D) Statistical analysis of ALDH1A1 protein levels in PANC-1, Capan-2 and AsPC-1 cells after treatment with CHX at 10 µM for the indicated times. (E) Western blotting analysis of ALDH1A1 protein levels in FBXL12-knockdown PANC-1, Capan-2 and AsPC-1 cells after treatment with CHX at 10 µM for the indicated times. (F) Statistical analysis of ALDH1A1 protein levels in shRNA-induced FBXL12-knockdown cells after treatment with CHX at 10 µM for the indicated times. (G) Immunofluorescence analysis of ALDH1A1 colocalization with FBXL12 in PANC-1 and Capan-2 cells. (H) Analysis of the interaction between FBXL12 and ALDH1A1 after transfection with the pCMV-Flag-FBXL12 vector by coimmunoprecipitation with an anti-Flag antibody followed by Western blotting analysis. (I) Analysis of the interaction between FBXL12 and ALDH1A1 after transfection with the pCMV-HA-ALDH1A1 vector by coimmunoprecipitation with an HA antibody followed by Western blotting analysis. (J) Analysis of ALDH1A1 ubiquitylation after FBXL12 knockdown or overexpression by coimmunoprecipitation. (K) Analysis of the ubiquitylation of ALDH1A1 by coimmunoprecipitation with an anti-ubiquitin antibody followed by Western blotting analysis with antibodies against the indicated proteins
Supplier Page from Abcam for Anti-FbxL12 antibody